Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
NCT07516405 · Psil-Pk · University of Colorado, Denver
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Adverse Events
Measured over up to 14 weeks
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
6 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| University of California San Francisco (UCSF) Department of Neurology | San Francisco | California | United States |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | United States |
| Emory University Brain Health Center | Atlanta | Georgia | United States |
| Dana-Farber Cancer Institute | Boston | Massachusetts | United States |
| University of Nebraska Medical Center | Omaha | Nebraska | United States |
| New York University Langone Health, Center for Psychedelic Medicine | New York | New York | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT07516405 on ClinicalTrials.gov →
Last updated in the registry 2026-08-10. Registry records change; this page reflects the data build of 2026-08-25.
Related